News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2021 Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI Michael O'Riordan June 07, 2021
News Conference News EAS 2019 Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019
News Conference News EAS 2018 Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention Yael L. Maxwell May 07, 2018
News Conference News EAS 2018 Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention Yael L. Maxwell May 07, 2018